Literature DB >> 22350116

Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors.

Tugrul Altan1, Nur Acar, Ziya Kapran, Yaprak B Unver, Sezin Ozdogan.   

Abstract

To evaluate the outcome of photodynamic therapy (PDT) and the factors influencing its outcome in patients with subfoveal choroidal neovascularization (CNV) due to pathologic myopia. Twenty-three eyes of 21 consecutive patients who received PDT for subfoveal CNV due to pathologic myopia and who were followed for >12 months were included in the study. The relationship between the factors that might affect the treatment outcome were evaluated. Mean age was 48.7 ± 16.0 years (23-74 years). Mean follow-up was 23.2 ± 7.7 months (15-41 months). Mean logMAR visual acuity was 0.85 ± 0.24 before treatment, 0.89 ± 0.37 at 12 months, and 0.92 ± 0.46 at the final visit. Mean logMAR visual acuity did not change significantly at 12 months or at the final visit (P = 0.47 and 0.36, respectively). The baseline visual acuity strongly correlated with the final visual acuity (P = 0.001). Age showed an inverse correlation with change in logMAR visual acuity at 12 months (P = 0.01). PDT prevented significant visual loss in eyes with subfoveal CNV due to pathologic myopia. Better initial visual acuity resulted in better final visual acuity. Younger age was correlated with better treatment outcome at 12 months.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350116     DOI: 10.1007/s10792-012-9532-6

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  28 in total

1.  Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization.

Authors:  S Mandal; P Venkatesh; R Sampangi; S Garg
Journal:  Eur J Ophthalmol       Date:  2007 Jul-Aug       Impact factor: 2.597

2.  Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy.

Authors:  Ilse Krebs; Susanne Binder; Ulrike Stolba; Carl Glittenberg; Werner Brannath; Alexandra Goll
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

3.  Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.

Authors: 
Journal:  Ophthalmology       Date:  2001-05       Impact factor: 12.079

4.  Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.

Authors:  Kevin J Blinder; Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donato; Hilel Lewis; Jennifer I Lim; Ugo Menchini; Joan W Miller; Jordi M Mones; Michael J Potter; Constantin Pournaras; Al Reaves; Philip Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenberg; Lawrence J Singerman; Jason S Slakter; H Andrew Strong; Gianni Virgili; George A Williams
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

5.  On the definition of pathologic myopia in group studies.

Authors:  T Tokoro
Journal:  Acta Ophthalmol Suppl       Date:  1988

6.  Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization.

Authors:  H Tabandeh; H W Flynn; I U Scott; M L Lewis; P J Rosenfeld; F Rodriguez; A Rodriguez; L J Singerman; J Schiffman
Journal:  Ophthalmology       Date:  1999-11       Impact factor: 12.079

7.  Visual prognosis of disciform degeneration in myopia.

Authors:  G R Hampton; D Kohen; A C Bird
Journal:  Ophthalmology       Date:  1983-08       Impact factor: 12.079

8.  Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia.

Authors:  Erdem Ergun; Harald Heinzl; Michael Stur
Journal:  Am J Ophthalmol       Date:  2004-09       Impact factor: 5.258

9.  Prevalence of myopia in the United States.

Authors:  R D Sperduto; D Seigel; J Roberts; M Rowland
Journal:  Arch Ophthalmol       Date:  1983-03

10.  Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.

Authors:  Yasushi Ikuno; Kaori Sayanagi; Kaori Soga; Miki Sawa; Motokazu Tsujikawa; Fumi Gomi; Yasuo Tano
Journal:  Am J Ophthalmol       Date:  2008-09-06       Impact factor: 5.258

View more
  2 in total

1.  A systematic review of clinical practice guidelines for myopic macular degeneration.

Authors:  Yanxian Chen; Xiaotong Han; Iris Gordon; Sare Safi; Gareth Lingham; Jennifer Evans; Jinying Li; Mingguang He; Stuart Keel
Journal:  J Glob Health       Date:  2022-03-26       Impact factor: 4.413

Review 2.  Myopic choroidal neovascularisation: current concepts and update on clinical management.

Authors:  Tien Y Wong; Kyoko Ohno-Matsui; Nicolas Leveziel; Frank G Holz; Timothy Y Lai; Hyeong Gon Yu; Paolo Lanzetta; Youxin Chen; Adnan Tufail
Journal:  Br J Ophthalmol       Date:  2014-07-01       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.